🇺🇸 FDA
Pipeline program

BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

GCT3013-05

Phase 3 small_molecule active

Quick answer

BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab for B-cell Lymphoma is a Phase 3 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Genmab A/S
Indication
B-cell Lymphoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials